LLY vs SKYE

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Skye Bioscience remains a highly speculative, high-risk/high-reward opportunity with potential for 10x growth, contingent on overcoming severe financial challenges. The company validated its novel cannabinoid-derived therapeutic approach with positive top-line Phase 2a data for SBI-100 (glaucoma) in November 2024, demonstrating significant clinical de-risking and a substantial TAM. However, this c...